TLE family member 6, subcortical maternal complex memberGenealiases: GRG6 · OZEMA15 · PREMBL
Q-omics provides the consensus-scored TLE6 profile across patient tissues and cancer cell-line models. TLE6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TLE6 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, TLE6 RNA expression shows 17,300 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where TLE6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLE6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLE6 survival associations across molecular data types. TLE6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLE6 RNA expression–survival associations across cancer types. High TLE6 expression shows unfavorable associations in KIRP, ACC, COAD, UCS, CESC and PRAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TLE6 RNA expression.
This table summarizes TLE6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TLE6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLE6 shows lower tumor expression in THCA, KIRC and LUSC and higher tumor expression in LIHC, BLCA and BRCA. The LIHC box plot shows higher TLE6 RNA expression in tumor versus normal tissue (log2 FC = +0.993, t-test p < 0.001).
This table shows molecular features associated with TLE6 in patient tissues and cancer cell lines. In patient samples, TLE6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TLE6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
